Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Troxacitabine (Shire Pharmaceuticals).

Gerhard Ecker1

  • 1Institute of Pharmaceutical Chemistry, University of Vienna, Austria. Gerhard.F.Ecker@univie.ac.at

Current Opinion in Investigational Drugs (London, England : 2000)
|November 15, 2002
PubMed
Summary

Shire Pharmaceuticals is investigating troxacitabine, a novel nucleoside analog, for treating acute myeloid leukemia (AML) and pancreatic cancer. Clinical trials are currently underway to evaluate its efficacy in patients with these conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Proteochemometric Model for Ligands of the SLC5 Transporter Family.

Archiv der Pharmazie·2026
Same author

The hepatocyte export carrier inhibition assay improves the separation of hepatotoxic from non-hepatotoxic compounds.

Chemico-biological interactions·2021
Same author

The RESOLUTE consortium: unlocking SLC transporters for drug discovery.

Nature reviews. Drug discovery·2020
Same author

Adverse outcome pathways: opportunities, limitations and open questions.

Archives of toxicology·2017
Same author

Synthesis and in silico evaluation of novel compounds for PET-based investigations of the norepinephrine transporter.

Molecules (Basel, Switzerland)·2015
Same author

Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease.

Bioorganic & medicinal chemistry letters·2014

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Acute myeloid leukemia (AML), pancreatic cancer, and solid tumors represent significant unmet medical needs.
  • Novel therapeutic agents are crucial for improving patient outcomes in these challenging malignancies.
  • Troxacitabine is a novel dioxolane nucleoside analog developed by Shire Pharmaceuticals.

Purpose of the Study:

  • To evaluate the potential of troxacitabine as a treatment for acute myeloid leukemia (AML).
  • To assess the efficacy of troxacitabine in patients with pancreatic cancer.
  • To explore the utility of troxacitabine in treating solid tumors.

Main Methods:

  • Phase I and II clinical studies are being conducted.
  • Patient populations include those with pancreatic cancer and AML.
  • The studies aim to assess safety and preliminary efficacy of troxacitabine.

Main Results:

  • Clinical studies are currently in progress.
  • Data on safety and efficacy are pending.
  • The development is being advanced by Shire Pharmaceuticals.

Conclusions:

  • Troxacitabine shows promise as a potential therapeutic agent for AML and pancreatic cancer.
  • Ongoing clinical trials will determine the ultimate role of troxacitabine in cancer treatment.
  • Further research is warranted to fully understand its therapeutic potential.

Related Experiment Videos